Application of inhaled bergamolactone nano-liposome in treatment of inflammatory lung injury

By using a carrier composed of DPPC, cholesterol and mPEG2000-DSPE, the inadequate efficacy of bergamot lactone in ALI treatment was solved, and more significant lung targeting was achieved. Better biosafety, inhibit M1 macrophages, promote M2 macrophages, and improve lung pathological damage.

CN118924708AActive Publication Date: 2024-11-12GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE +1

Patent Information

Application Number
CN202411160763.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-12
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The efficacy of the existing bergamot lactone in the treatment of acute lung injury (ALI) is only close to that of positive drugs, and has not been significantly improved. The drug loading and stability of nanoliposomes are insufficient, which affects the efficacy.

Method used

Inhaled bergamot lactone nanoliposomes using DPPC, cholesterol and mPEG2000-DSPE as carriers, the lung targeting and stability of nanoliposomes were improved by adjusting the molar ratio and preparation conditions, and the M1 macrophages were inhibited. to promote M2 macrophage polarization.

Benefits of technology

It significantly improved the efficacy of bergamot lactone in ALI treatment, reduced the expression of inflammatory factors in lung tissues, enhanced lung targeting and biosafety, inhibited M1 macrophages, promoted M2 macrophages, and improved lungs. pathological injury.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005006336480000011
    Figure HDA0005006336480000011
  • Figure HDA0005006336480000012
    Figure HDA0005006336480000012
  • Figure HDA0005006336480000021
    Figure HDA0005006336480000021
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to application of inhaled bergamolactone nano-liposome to treatment of inflammatory lung injury. According to the inhalation type bergamolactone nano-liposome provided by the invention, bergamolactone is used as a raw medicine, and DPPC, cholesterol and mPEG2000-DSPE are used for constructing a nano-liposome carrier, so that the bergamolactone nano-liposome with lung targeting property is formed and can act on the lung in a targeting manner in an aerosol inhalation manner, and the lung targeting property of the inhaled bergamolactone nano-liposome is improved; when being used for treating lipopolysaccharide-induced acute lung injury, the compound can inhibit polarization of M1 macrophages in lung tissues and promote polarization of M2 macrophages in the lung tissues, so that lung inflammation is inhibited, pulmonary edema is relieved, pathological injury of the lung tissues is improved, and the like. And the bergamolactone monomer has a more obvious effect of improving the phenotype of the acute lung injury than a free bergamolactone monomer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to application of inhaled bergamot lactone nanoliposomes in treating inflammatory lung injury, and relates to the technical field of medicine. Background Art

[0002] Acute lung injury (ALI) refers to a disease characterized by pulmonary diffusion dysfunction caused by multiple direct or indirect factors such as trauma, infection, inhalation of harmful gases, shock, etc., with a mortality rate of up to 30% to 50%. The pathogenesis of ALI is complex, and the pathological process mainly includes three stages: acute exudative phase, lung tissue repair and remodeling phase, and chronic phase. In the acute exudative phase, pulmonary vascular endothelial cells and type I alveolar epithelial cells are damaged, a large number of inflammatory cells diffusely infiltrate in the lung tissue, inflammatory factors in the lung are excessively released, and alveolar edema occurs; in the lung tissue repair and remodeling phase, pulmonary interstitial fibroblasts proliferate and perform abnormal repair and remodeling of lung tissue; in the chronic phase, if the lung tissue is excessively repaired and remodeled, it will develop into pulmonary fibrosis. Currently, drugs used to treat ALI include glucocorticoids, anti-oxidative stress drugs, non-steroidal anti-inflammatory drugs, etc. Different drugs can treat ALI patients through different action processes.

[0003] Bergamot lactone, also known as 5-methoxypsoralen, belongs to the coumarin class of compounds and is one of the active ingredients of plants such as bergamot, angelica, and angelica. Its molecular formula is C 12 H 8 O 4 . In recent years, various studies have confirmed that bergamot lactone has anti-inflammatory and anti-cancer effects. Among them, Chinese patent CN116687915A discloses the application of bergamot lactone in the treatment of lung injury. When bergamot lactone is used to treat ALI, the efficacy is basically similar to that of the positive drug pirfenidone, which proves that bergamot lactone has good application prospects in the treatment of ALI. However, the best therapeutic effect of bergamot lactone in the prior art has only reached a level close to that of the positive drug, and has not been significantly improved. Summary of the invention

[0004] According to one aspect of the present invention, an inhalable bergamot lactone nanoliposome is provided, comprising an original drug and a carrier, wherein the original drug is bergamot lactone, and the carrier is DPPC (dipalmitoylphosphatidylcholine), cholesterol and mPEG2000-DSPE (polyethylene glycol monomethyl ether-2000-dioctadecylphosphatidylethanolamine, CAS147867-65-0), and the molar ratio of DPPC, cholesterol and mPEG2000-DSPE in the carrier is (70-85): (15-25): 3.

[0005] DPPC in the inhalable bergamot lactone nanoliposome provided by the present invention is a surfactant component in lung tissue, so it has lung targeting, and can give the bergamot lactone nanoliposome the characteristic of targeting to the lung. The applicant was surprised to find that after preparing bergamot lactone into a nanoliposome dosage form and administering it, the polarization of M1 macrophages in lung tissue can be inhibited, while promoting the polarization of M2 macrophages in lung tissue, and it has a more significant effect than the free bergamot lactone monomer in the treatment of ALI. It should be noted that the molar ratio of each component in the liposome carrier will affect the encapsulation rate of the liposome to the original drug and its drug loading. The excessive amount of DPPC and cholesterol in the carrier and the excessively low amount of mPEG2000-DSPE are likely to lead to too low drug concentration in the liposome. When intervening cells, it is necessary to add excessive liposomes to achieve a certain therapeutic effect, but the excessive amount of liposomes is likely to affect cell growth and cause cell contamination, and the liposomes obtained therefrom have no obvious advantages in the in vitro anti-inflammatory effect compared with the monomer bergamot lactone.

[0006] In some embodiments, the molar ratio of bergamot lactone to DPPC in the inhalable bergamot lactone nanoliposome is 1:(1.5-4.5).

[0007] In some embodiments, the drug concentration of bergamot lactone in the inhalable bergamot lactone nanoliposomes is 0.5 to 1.5 mmol / L.

[0008] In some embodiments, the drug loading amount of bergamot lactone in the inhalable bergamot lactone nanoliposomes is 0.45% to 0.60%.

[0009] In some embodiments, the encapsulation efficiency of bergamot lactone in the inhalable bergamot lactone nanoliposome is 5% to 8%.

[0010] In some embodiments, the zeta potential of the inhalable bergamot lactone nanoliposomes is -6 to -8 mV.

[0011] The larger the absolute value of Zeta potential, the higher the stability of the nanomaterial. The absolute value of Zeta potential of the nanoliposomes in the present invention reaches 6 to 8, indicating that the liposomes have good stability. At the same time, the Zeta potential of the nanoliposomes is negative, indicating that they may be able to enhance the diffusion efficiency in respiratory mucus by reducing the interaction with negatively charged respiratory mucins.

[0012] In some embodiments, the inhalable bergamot lactone nanoliposomes are spherical with an average diameter of 105-120 nm.

[0013] According to another aspect of the present invention, a method for preparing inhalable bergamot lactone nanoliposomes is provided, comprising the following steps:

[0014] S1. dissolving DPPC, cholesterol, mPEG2000-DSPE and bergamot lactone in a solvent, and removing the solvent to form a film;

[0015] S2. Add an aqueous medium to the film formed in step S1, and fully hydrate and peel off the film at 50-70° C. to obtain inhalable bergamot lactone nanoliposomes.

[0016] The temperature of the film hydration in step S2 has an important influence on the preparation of the liposomes in the present invention. If the temperature is too high, it is easy to affect the activity of the monomers, and if the temperature is too low, it is easy to cause an insufficient hydration process, and the temperature also affects the Zeta potential of the obtained liposomes. When the film is hydrated and detached at 50-70°C, the obtained liposomes can be fully hydrated and have a suitable Zeta potential, and the monomers in the liposomes still have excellent activity.

[0017] In some embodiments, the solvent in step S1 is chloroform.

[0018] In some embodiments, in step S1, DPPC, cholesterol and mPEG2000-DSPE are first dissolved in chloroform, and then bergamot lactone is dissolved in chloroform and then added into the reaction system.

[0019] In some embodiments, step S1 removes the solvent by rotary evaporation at 230 mbar.

[0020] In some embodiments, the aqueous medium in step S2 is PBS buffer.

[0021] In some embodiments, after the aqueous medium is added in step S2, the film is fully hydrated by magnetic stirring, and the speed of the magnetic stirrer is 300 rpm.

[0022] If the magnetic stirring speed is too high, foam is easily generated, and the system produces multiple phase interfaces, resulting in uneven properties and affecting the various properties of the liposomes; if the speed is too low, hydration is insufficient.

[0023] In some embodiments, when fully hydrating the film in step S2, the reaction system may be manually rotated to allow the aqueous medium to fully contact the film, thereby assisting in hydration of the film.

[0024] In some embodiments, the time for fully hydrating the film in step S2 is 30 minutes.

[0025] In some embodiments, after the hydration in step S2 is completed, the steps of ultrasonic dispersion, filtration, ultrafiltration and volume determination are further included.

[0026] In some embodiments, the ultrasonic dispersion step is as follows: placing the suspension obtained by fully hydrating and shedding the thin film on ice for ultrasonication, with an ultrasonic power of 20%, and an ultrasonic method of pausing for 15 seconds after every 15 seconds of ultrasonication, and ending the ultrasonication after 30 minutes to obtain a suspension after ultrasonic dispersion.

[0027] In some embodiments, the filtering step is as follows: filtering and collecting the suspension after ultrasonic dispersion using a 0.22 μm filter, repeating the process three times to obtain a filtrate.

[0028] In some embodiments, the ultrafiltration step is: centrifugal ultrafiltration of the filtrate obtained by filtration at a rotation speed of 3000 rpm for 1 hour, and purified bergamot lactone nanoliposomes are obtained after the centrifugation. The purpose of this step is to remove excess nanoliposomes and free bergamot lactone monomers.

[0029] In some embodiments, the step of fixing the volume is: using PBS buffer to fix the volume of the purified bergamot lactone nanoliposomes to 3 mL to obtain an inhalable bergamot lactone nanoliposome solution for later use.

[0030] According to another aspect of the present invention, there is provided a use of inhalable bergamot lactone nanoliposomes in a drug for treating acute lung injury.

[0031] In some embodiments, the drug for treating acute lung injury is administered by aerosol inhalation.

[0032] Administration by aerosol inhalation allows nanoliposomes to better target the lungs and reach the lesions directly. Compared with oral administration and other methods of administration, it has better lung targeting and better biological distribution.

[0033] According to another aspect of the present invention, there is provided a use of inhaled bergamot lactone nanoliposomes in a drug for inhibiting the expression of M1 macrophages.

[0034] According to another aspect of the present invention, there is provided a use of inhalable bergamot lactone nanoliposomes in a drug for promoting the expression of M2 macrophages.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] The inhalable bergamot lactone nanoliposomes provided by the present invention have good biosafety, can act on the lungs in a targeted manner through aerosol inhalation, reduce the expression levels of inflammatory factors IL-6, IL-1β and TNF-α in lung tissue, and can inhibit the polarization of M1 macrophages in lung tissue and promote the polarization of M2 macrophages in lung tissue, and have a more significant effect than free bergamot lactone monomers in the treatment of ALI. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 Schematic diagram of the comparison of particle sizes of the inhalable bergamot lactone nanoliposomes in Example 1 of the present invention and the nanoliposomes in Comparative Example 1;

[0038] Figure 2 The transmission electron micrographs of the inhalable bergamot lactone nanoliposomes in Example 1 of the present invention and the nanoliposomes in Comparative Example 1;

[0039] Figure 3 Schematic diagram of the comparison of the zeta potential of the inhalable bergamot lactone nanoliposomes in Example 1 of the present invention and the nanoliposomes in Comparative Example 1;

[0040] Figure 4 The effects of different groups of the present invention on the HUVEC cytoskeleton;

[0041] Figure 5 The effects of different concentrations of the inhalable bergamot lactone nanoliposomes in Example 1 of the present invention, the nanoliposomes and the free bergamot lactone monomers in Comparative Example 1 on the viability of RAW264.7 cells;

[0042] Figure 6 The effects of different concentrations of the inhalable bergamot lactone nanoliposomes in Example 1 of the present invention, the nanoliposomes in Comparative Example 1 and the free bergamot lactone monomers on HUVEC cell viability;

[0043] Figure 7 Schematic diagram of the compatibility of different concentrations of inhalable bergamot lactone nanoliposomes and free bergamot lactone monomers with blood in Example 1 of the present invention;

[0044] Figure 8 The effects of different groups of the present invention on the mRNA of pro-inflammatory factors IL-6, IL-1β and TNF-α in RAW264.7 cells treated with LPS;

[0045] Fig. 9 The effects of different groups of the present invention on the fluorescence intensity and distribution of macrophage polarization indicators CD86 and CD163;

[0046] Fig.10 The effect of different groups of the present invention on the protein expression of macrophage polarization indicators CD86 and CD163;

[0047] Fig.11 This is a statistical diagram of the protein expression results of macrophage polarization indexes CD86 and CD163 in different groups of the present invention;

[0048] Fig.12 The effects of different groups of the present invention on the mRNA of macrophage polarization indicators CD86, iNOS and CD206;

[0049] Fig.13 The effects of different groups of the present invention on the lung index of ALI mice induced by LPS;

[0050] Fig.14 The effect of different groups of the present invention on the total cell number in the bronchoalveolar lavage fluid of ALI mice induced by LPS;

[0051] Fig.15 The effect of different groups of the present invention on the total protein concentration in the bronchoalveolar lavage fluid of ALI mice induced by LPS;

[0052] Fig.16 The effects of different groups of the present invention on the pathological damage of lung tissues in ALI mice induced by LPS;

[0053] Fig.17 The effects of different groups of the present invention on the mRNA of pro-inflammatory factors IL6, IL1-β and TNFα in the lung tissue of ALI model mice induced by LPS;

[0054] Fig.18 The effects of different groups of the present invention on the fluorescence expression intensity and distribution of macrophage polarization indicators CD86, iNOS, CD163 and CD206 in the lung tissue of ALI model mice induced by LPS;

[0055] Fig.19 The effects of different groups of the present invention on the protein expressions of macrophage polarization indexes CD86, CD163 and CD206 in the lung tissue of ALI model mice induced by LPS;

[0056] Fig. 20 The figure is a statistical diagram of the protein expression results of macrophage polarization indexes CD86, iNOS, CD163 and CD206 in the lung tissue of ALI model mice induced by LPS in different groups of the present invention.

[0057] Fig.21 The present invention shows the influence of different groups on the mRNA expression of macrophage polarization indexes CD86, iNOS, CD163 and CD206 in the lung tissue of ALI model mice induced by LPS. DETAILED DESCRIPTION

[0058] The present invention is further described in detail below in conjunction with the examples and drawings, but the implementation of the present invention is not limited thereto. The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from the market unless otherwise specified.

[0059] Example 1

[0060] An inhalable bergamot lactone nanoliposome, denoted as Ber-lipo, comprises a raw drug and a carrier, wherein the raw drug is bergamot lactone, the carrier is DPPC, cholesterol and mPEG2000-DSPE, the molar ratio of DPPC, cholesterol and mPEG2000-DSPE in the carrier is 77:20:3, and the molar ratio of bergamot lactone to DPPC in the inhalable bergamot lactone nanoliposome is 1:3.13;

[0061] The drug loading amount of bergamot lactone in the inhalable bergamot lactone nanoliposomes is 0.52%, the drug concentration is 1mmol / L, the encapsulation efficiency is 6.5%, the nanoliposomes are uniform spherical, the average diameter is 111.2nm, and the Zeta potential is -7mV.

[0062] The preparation method of inhalable bergamot lactone nanoliposomes in this embodiment comprises the following steps:

[0063] S1. 106.2 mg of DPPC, 14.5 mg of cholesterol and 4.8 mg of mPEG2000-DSPE were dissolved in 5 mL of chloroform, and then 10 mg of bergamot lactone was dissolved in chloroform, and then added to the reaction system, and the solvent was removed by rotary evaporation at 230 mbar to form a film;

[0064] S2. Add PBS buffer to the film formed in step S1, and perform magnetic stirring at 60°C for 30 minutes to fully hydrate the film at a rotation speed of 300 rpm; during this period, manually rotate the reaction system to allow the aqueous medium to fully contact the film to assist in hydration of the film; after the film is fully hydrated and falls off to obtain a suspension, place it on ice for ultrasonication, the ultrasonic power is 20%, the ultrasonic method is to pause for 15 seconds after each ultrasonication for 15 seconds, and the ultrasonication is terminated after 30 minutes, and the suspension after ultrasonic dispersion is collected by filtration using a 0.22 μm filter, and the filtrate obtained by filtration is repeated three times to obtain a filtrate, and the filtrate obtained by filtration is subjected to centrifugal ultrafiltration at a rotation speed of 3000 rpm for 1 hour. After the centrifugation is completed, purified bergamot lactone nanoliposomes are obtained, and the purified bergamot lactone nanoliposomes are fixed to 3 mL using PBS buffer to obtain an inhalable bergamot lactone nanoliposome solution for standby use.

[0065] Comparative Example 1

[0066] A nanoliposome, denoted as Lipo, includes only a carrier, wherein the carrier is DPPC, cholesterol and mPEG2000-DSPE, and the molar ratio of DPPC, cholesterol and mPEG2000-DSPE in the carrier is 77:20:3;

[0067] The nanoliposomes were uniform spherical in shape with an average diameter of 116.1 nm and a Zeta potential of -9 mV.

[0068] The preparation method of nanoliposomes in this comparative example is carried out according to Example 1, wherein the difference from Example 1 is only that:

[0069] In step S1, bergamot lactone is not added.

[0070] The substances obtained in Example 1 and Comparative Example 1 were characterized, and the experimental results are as follows: Figures 1 to 3 As shown: the size of the nanoliposomes obtained in Comparative Example 1 is in the range of 30-470nm, the size of the inhalable bergamot lactone nanoliposomes obtained in Example 1 is in the range of 40-340nm, and the average sizes of the liposomes obtained in Comparative Example 1 and Example 1 are about 116.1nm and 111.2nm, respectively. Zeta potential shows that the nanoliposomes Lipo obtained in Comparative Example 1 and the inhalable bergamot lactone nanoliposomes Ber-lipo obtained in Example 1 are both negatively charged, with average potentials of -9mV and -7mV, respectively. Transmission electron microscopy observation results show that the nanoliposomes Lipo obtained in Comparative Example 1 and the inhalable bergamot lactone nanoliposomes Ber-lipo obtained in Example 1 have uniform spherical morphology with a diameter of about 115nm, which is consistent with the results measured by DLS.

[0071] Comparative Example 2

[0072] A bergamot lactone nanoliposome, denoted as Ber-lipo-2, comprises a raw drug and a carrier, wherein the raw drug is bergamot lactone, the carrier is DPPC, cholesterol and mPEG2000-DSPE, the molar ratio of DPPC, cholesterol and mPEG2000-DSPE in the carrier is 29:14:1, and the molar ratio of bergamot lactone and DPPC in the bergamot lactone nanoliposome is 1:1.2;

[0073] The drug concentration of bergamot lactone in bergamot lactone nanoliposomes is 0.2mmol / L.

[0074] The preparation method of nanoliposomes in this comparative example is carried out according to Example 1, wherein the difference from Example 1 is:

[0075] Step S1: Add 39.7 mg DPPC, 10.1 mg cholesterol, 1.6 mg mPEG2000-DSPE and 10 mg bergamot lactone.

[0076] In this comparative example, the drug concentration of bergamot lactone in the liposome is too low, and a large amount of liposomes needs to be added when intervening in cells, which affects cell growth.

[0077] Experimental study on the pharmacological effects of inhaled bergamot lactone nanoliposomes

[0078] Next, cell and animal experiments were conducted using the inhalable bergamot lactone nanoliposomes Ber-lipo prepared in Example 1, the nanoliposomes Lipo in Comparative Example 1, and the free bergamot lactone monomer Bergapten to explore their pharmacological effects.

[0079] 1. Cell experiments and related index determination

[0080] 1. Effect of Ber-lipo on the cytoskeleton of HUVECs

[0081] Cytoskeleton staining was performed according to the instructions of the FITC Phalloidin staining kit. HUVECs were seeded in 0.17 mm glass-bottom culture dishes. When the cells grew to a density of 60%-70% in a 37°C incubator, DMEM complete medium containing 40 μmol / L Bergapten, 40 μmol / L Ber-lipo and Lipo (equal volume to Ber-lipo) was added, and PBS equal to the volume of Ber-lipo was added to the culture medium of the Control group. After intervention with drug-containing culture medium for 12 h and 24 h, the drug-containing culture medium was removed, and 4% paraformaldehyde was added to fix for 10 min; then 0.5% Triton X-100 and BSA were added in turn to permeabilize and block the cells. Finally, the cytoskeleton and cell nucleus were stained for 30 min, respectively. After washing with PBS three times, images were collected using a laser scanning confocal microscope to obtain Figure 4 .

[0082] Figure 4 The results showed that compared with the Control group, the cell morphology of the Lipo, Bergapten and Ber-lipo groups was normal, which indicates that the Ber-lipo of the present invention has no effect on the cell morphology and has good biosafety.

[0083] 2. Effect of Ber-lipo on RAW264.7 cell viability

[0084] Cell Counting Kit-8 (CCK-8) was used to determine the toxicity of drugs to RAW264.7 cells. RAW264.7 cells were cultured at 1×10 4 / well density was inoculated in a 96-well culture plate (the volume of each well was 100μL) and cultured for 24h. DMEM complete medium (Gibico, C11995500BT; 10% serum from ExCell and 1% double antibody from Solebo were added before use) was used as solvent to prepare 2.5μM, 5μM, 10μM, 20μM, 40μM concentration gradients of Bergapten, Ber-lipo and Lipo (Lipo and Ber-lipo were equal in volume). The control group used PBS with the same volume as Ber-lipo instead, and the cells were treated with the prepared culture medium. After 24h of intervention, the supernatant was discarded, 10μL of CCK-8 solution and 100μL of complete culture medium were added to each well, and the wells were incubated at 37℃ in the dark for 1-2h, and the absorbance of each well was measured at a wavelength of 450nm.

[0085] Figure 5 The results showed that within the concentration range of 2.5-40 μM, the Ber-lipo of the present invention had almost no effect on the viability of cells, and at 40 μM, the cell viability was better than that of the free monomer group.

[0086] 3. Effects of different concentrations of Ber-lipo on HUVEC cell viability

[0087] CCK-8 was used to determine the toxicity of drugs to HUVEC cells. HUVEC cells were cultured at 5×10 3 The cells / well were inoculated in a 96-well culture plate at a density of 1.5 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, and 80 μM of Bergapten, Ber-lipo, and Lipo were prepared with complete culture medium. The control group used PBS with an equal volume of Ber-lipo instead, and the cells were treated with the prepared culture medium. After 24 hours of intervention, the supernatant was discarded, and 10 μL of CCK-8 solution and 100 μL of complete culture medium were added to each well, incubated at 37°C in the dark for 1-2 hours, and the absorbance of each well was measured at a wavelength of 450 nm.

[0088] Figure 6 The results showed that within the concentration range of 2.5-40 μM, Ber-lipo of the present invention had little effect on cell viability. When the concentration increased to 80 μM, Ber-lipo showed certain toxicity. Figure 5 and Figure 6 Taking into account the results, Ber-lipo selected a concentration of 40 μM to intervene in cells and animals.

[0089] 4. Schematic diagram of compatibility of different concentrations of Ber-lipo with blood

[0090] Take 2mL of normal mouse whole blood, add 1000U / mL heparin sodium solution and centrifuge (5000rpm, 5min, room temperature), discard the upper plasma, dilute and resuspend the precipitate with an appropriate amount of physiological saline, and wash 3 times until the supernatant is bloodless. Take an appropriate amount of red blood cells from the lower layer in a centrifuge tube, add physiological saline to prepare a 2% red blood cell solution, and then add 10μM, 20μM, 40μM, 80μM, 160μM Lipo, Bergapten and Ber-lipo respectively. Pure water and PBS are used as positive and negative controls respectively. After standing at room temperature for 3h, centrifuge at 1000rpm for 5min and take photos and record them. Then aspirate the supernatant and detect it on an enzyme reader at 540nm to calculate the hemolysis rate. Hemolysis rate = (Aa-A0) / (Ab-A0)×100%. (Aa, A0 and Ab are the absorbance of the experimental group, negative control group and positive control group respectively)

[0091] Figure 7 The results show that the Ber-lipo of the present invention is incompatible with blood and has good biocompatibility.

[0092] 5. Effect of Ber-lipo on mRNA expression of pro-inflammatory factors IL-6, IL-1β and TNF-α in RAW264.7 cells induced by LPS

[0093] RAW264.7 cells were seeded in 12-well plates. When the density reached 60%-70%, serum-free medium was replaced. Bergapten, Ber-lipo and an equal volume of Lipo were added to make the concentration in the medium 40μM. PBS (equal volume to Ber-lipo) was added to the Control and Model groups. After 12h, serum-free medium was replaced again. The Model group and the drug group were stimulated with medium containing 100ng / mL LPS for 4h. The Control group was given a medium containing PBS buffer at the same concentration, and then fresh serum-free medium was replaced. Drug intervention was added in the same way for 6h (PBS buffer was used instead of drugs in both the Control and Model groups). After the experimental intervention, cells were collected to extract RNA. Total RNA of RAW264.7 cells was extracted according to the instructions of the RNA extraction kit (Tiangen Biotech, China), the extracted RNA content was determined by Nanodrop, and the mRNA was reverse transcribed into cDNA using the PrimeScript RT kit (Takara Bio, China). Using the cDNA of each sample as a template, qRT-PCR amplification was performed to detect and analyze the mRNA expression of each target gene (IL-6, IL-1β, TNF-α and Tubulin). After the reaction, Tubulin was used as the internal reference gene and 2 -ΔΔCTMethods The relative expression of each gene was calculated. The primer sequences used are as follows:

[0094] TNF-α-F:TTGTCTACTCCCAGGTTCTCT;

[0095] TNF-α-R:GAGGTTGACTTTCTCCTGGTATG;

[0096] IL-1β-F:GGTGTGGTGACGTTCCCATTA;

[0097] IL-1β-R:ATTGAGGTGGAGAGCTTTCAG;

[0098] IL-6-F:CTTCCATCCAGTTGCCTTCT;

[0099] IL-6-R:CTCCGACTTGTGAAGTGGTATAG;

[0100] Tubulin-F:AGCAGCTACTTTGTGGAGTG;

[0101] Tubulin-R:TCGGAGATGCGCTTGAATAG.

[0102] Figure 8 The results showed that Ber-lipo of the present invention could significantly reduce the increase in mRNA content of pro-inflammatory factors IL-6, IL-1β and TNF-α caused by LPS stimulation, and inhibit the inflammation of RAW264.7 cells.

[0103] 6. Effect of Ber-lipo on the fluorescence intensity and distribution of macrophage polarization indicators CD86 and CD163

[0104] RAW264.7 cells were inoculated in 0.17 mm glass-bottomed culture dishes. When the density reached 60%-70%, 100 ng / mL LPS was used to intervene the cells. The control group was intervened with an equal volume of PBS. In the drug-treated group, Bergapten, Ber-lipo and Lipo were added to the culture dish to make the concentration 40 μM, and the Model group and the Control group were given an equal volume of PBS buffer to replace the drug with Ber-lipo. After 24 hours of intervention, the cells were collected and immunofluorescence staining was performed. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.5% Triton X-100 (PBS dilution) for 10 minutes, and blocked with 5% BSA (PBS dilution) for 1 hour; CD86 (Proteintech, 13395-1-AP, 1:500) and CD163 (Proteintech, 16646-1-AP, 1:500) primary antibody dilutions were incubated at 4°C overnight. The next day, the cells were incubated with the corresponding Cy3 fluorescent secondary antibody (Biolegend, 406402, 1:200) at room temperature in the dark for 1 h; the cell nuclei were counterstained with DAPI for 20 min; and the images were taken with a Zeiss laser confocal microscope at 63× oil objective.

[0105] Fig. 9 The results showed that compared with the Control group, the fluorescence intensity of CD86 in the Model group was significantly enhanced, and the fluorescence intensity of CD163 was significantly reduced, while compared with the Model group, the fluorescence intensity of CD86 in the Bergapten and Ber-lipo groups was significantly reduced, and the fluorescence intensity of CD163 was increased. CD86 is a marker for M1 macrophage polarization, and CD163 is a marker for M2 macrophage polarization, which shows that Ber-lipo of the present invention can inhibit the polarization of M1 macrophages and promote the polarization of M2 macrophages.

[0106] 7. Effect of Ber-lipo on the expression of macrophage polarization indicators CD86 and CD163 proteins

[0107] RAW264.7 cells were seeded in a 6-well plate. When the density was 60%-70%, 100 ng / mL of LPS was added to stimulate the cells. The control group was replaced with PBS buffer. In the drug-treated group, Bergapten, Ber-lipo and Lipo were added to the culture dish to make the concentration 40 μM, and the control group and the model group added PBS equal to the volume of Ber-lipo. The cells were collected after 24 hours of intervention. RIPA, PMSF and phosphatase inhibitors were mixed and added to the cells at a volume ratio of 100:1:1, shaken on ice for 30 minutes, centrifuged at 4°C and 12000 rpm for 10 minutes, and the supernatant was collected and the protein concentration was measured with a BCA kit. The cell protein sample with the measured concentration was added with SDS-PAGE protein loading buffer, boiled at 95°C for 10 minutes, and then loaded onto the pre-prepared gel for SDS-PAGE electrophoresis separation, 80v30min, 120v 1.5h, and transferred to the membrane at 250mA for 2h after the electrophoresis. After the transfer, the membrane was transferred to a 5% skim milk powder culture dish and blocked for 2 hours on a shaker, and then incubated with primary antibodies for CD86 (Proteintech, 13395-1-AP, 1:2000) and CD163 (Proteintech, 16646-1-AP, 1:1000) at 4°C overnight. The next day, after TBST washing, the membrane was incubated with the corresponding secondary antibody for another 1 hour at room temperature. Finally, the protein bands on the membrane were imaged using a chemiluminescence imaging system.

[0108] Fig.11 The results showed that the protein bands of RAW264.7 cells stimulated by LPS increased the expression of CD86 and decreased the expression of CD163 compared with the control group. After Bergapten and Ber-lipo treatment, the intensity of CD86 protein bands weakened, while the intensity of CD163 protein bands increased. Fig.10 The grayscale value of the protein bands showed that the decrease in CD86 in the Ber-lipo group was more obvious than that in the Bergapten group, and the increase in CD163 was also more significant than that in the Bergapten group, and the differences between the two were statistically significant. This shows from the protein level that Bergapten and Ber-lipo of the present invention can inhibit the polarization of M1 macrophages and promote the polarization of M2 macrophages, and the effect of Ber-lipo is better than that of Bergapten.

[0109] 8. Effect of Ber-lipo on mRNA of macrophage polarization indicators CD86, iNOS and CD206

[0110] RAW264.7 cells were seeded in a 12-well plate. When the density reached 60%-70%, 100 ng / mL of LPS was added to stimulate the cells. The control group was given PBS buffer instead of drugs. In the drug-treated group, Bergapten, Ber-lipo and Lipo were added to the culture dish to make the concentration 40 μM, and the control group and the model group were added with PBS of the same volume as Ber-lipo. The cells were collected after 24 hours of intervention. Total RNA was extracted according to the instructions of the RNA extraction kit (Tiangen Biotech, China), the extracted RNA content was determined by Nanodrop, and the mRNA was reverse transcribed into cDNA using the PrimeScript RT kit (Takara Bio, China). Using the cDNA of each sample as a template, the target genes (CD86, CD206, iNOS and Tubulin) were amplified by qRT-PCR to analyze the mRNA expression of each target gene. After the reaction, Tubulin was used as the internal reference gene and 2 -ΔΔCT Methods The relative expression of each gene was calculated. The primer sequences used are as follows:

[0111] CD86-F:CGCAAGCTTATTTCAATGGGA;

[0112] CD86-R:CCTGCCAAAATACTACCAG;

[0113] iNOS-F:GGAATCTTGGAGCGAGTTGT;

[0114] iNOS-R:CCTCTTGTCTTTGACCCAGTAG;

[0115] CD206-F:TTCCGTCACCCTGTATGCC;

[0116] CD206-R:TAACTCTGTGCCCTTGATTCCA;

[0117] Tubulin-F:AGCAGCTACTTTGTGGAGTG;

[0118] Tubulin-R:TCGGAGATGCGCTTGAATAG;

[0119] Fig.12The results showed that compared with the Control group, the mRNA levels of CD86 and iNOS in the Model group were significantly increased, and the mRNA level of CD206 was significantly decreased. Compared with the Model group, the Bergapten and Ber-lipo groups showed the opposite trend, and there was a significant difference between the Ber-lipo group and the Bergapten group. The mRNA level proved that the Ber-lipo of the present invention can inhibit the polarization of M1 macrophages and promote the polarization of M2 macrophages.

[0120] 2. Animal experiments and related index determination

[0121] 1. Animal grouping and modeling

[0122] After anesthesia, mice were induced by intratracheal injection of 5 mg / kg LPS to establish an ALI model (no fasting required). The control group was replaced with PBS equal to the volume of LPS, which was recorded as day 0. Then, mice inhaled 6 mL, 40 μM Bergapten, Ber-lipo and Lipo (equal volume to Ber-lipo) twice a day by nebulization, and the model group and the control group inhaled PBS equal to the volume of Ber-lipo by nebulization, each inhalation lasting 20 minutes. Mice were killed 72 hours after infection (day 3), and samples were collected and indicators were detected.

[0123] 2. Determination of relevant indicators

[0124] 1) Effect of Ber-lipo on lung index of LPS-induced ALI mice

[0125] When mice were sacrificed, the whole fresh lung tissue of each mouse was collected and weighed (W1). The weight of mice was recorded at the time of sacrifice (W2). The lung coefficient was calculated according to the formula W1 / W2×100%.

[0126] Fig.13 The results showed that Ber-lipo of the present invention significantly reduced the increase in the lung index of ALI mice caused by LPS and alleviated lung edema.

[0127] 2) Effects of Ber-lipo on total cell number and total protein in bronchoalveolar lavage fluid of LPS-induced ALI mice

[0128] After the mice were anesthetized with 3% chloral hydrate, their limbs were fixed, and a catheter was inserted into the mouse trachea through a small incision in the neck and fixed. The mice were irrigated with pre-cooled sterile saline or PBS, 0.7 mL each time, and repeated three times. The collected irrigated fluid was centrifuged at 4°C and 3000 rpm for 10 minutes to detect total protein concentration and total cell count.

[0129] Fig.14 and Fig.15The results showed that compared with the LPS-induced Model group, the Ber-lipo of the present invention significantly reduced the total cell count and total protein concentration in the bronchoalveolar lavage fluid of ALI model mice and enhanced the permeability of the lungs.

[0130] 3) Effect of Ber-lipo on pathological damage of lung tissue in LPS-induced ALI mice

[0131] Fresh lung tissue was fixed in 4% paraformaldehyde solution for 24 hours, then embedded in paraffin and sliced ​​to a thickness of 4 μm. The slides were picked up and dried, and stained with hematoxylin and eosin according to the procedure. The stained slides were dried, sealed, and finally photographed under an optical microscope.

[0132] Fig.16 The results showed that compared with the model group, the lung tissue had obvious inflammatory cell infiltration (black arrow), alveolar wall thickening (red arrow), inflammatory exudation (green arrow), and obvious alveolar structural destruction. The Ber-lipo treatment group significantly improved the above damage.

[0133] 4) Effect of Ber-lipo on the mRNA expression of pro-inflammatory factors IL-6, IL-1β and TNF-α in lung tissue of LPS-induced ALI model mice

[0134] According to the instructions of RNA extraction kit (Tiangen Biotechnology, DP419), total RNA of lung tissue was extracted, the extracted RNA content was determined by Nanodrop, and the mRNA was reverse transcribed into cDNA using PrimeScript RT kit (Takara, RR047B). Using the cDNA of each sample as a template, qRT-PCR amplification was performed to detect and analyze the mRNA expression of each target gene (IL-6, IL-1β, TNF-α and Tubulin). After the reaction, Tubulin was used as the internal reference gene and 2 -ΔΔCT Methods The relative expression of each gene was calculated. The primer sequences used are as follows:

[0135] TNF-α-F:TTGTCTACTCCCAGGTTCTCT;

[0136] TNF-α-R:GAGGTTGACTTTCTCCTGGTATG;

[0137] IL-1β-F:GGTGTGGTGACGTTCCCATTA;

[0138] IL-1β-R:ATTGAGGTGGAGAGCTTTCAG;

[0139] IL-6-F:CTTCCATCCAGTTGCCTTCT;

[0140] IL-6-R:CTCCGACTTGTGAAGTGGTATAG;

[0141] Tubulin-F:AGCAGCTACTTTGTGGAGTG;

[0142] Tubulin-R:TCGGAGATGCGCTTGAATAG.

[0143] Fig.17 The results showed that Ber-lipo of the present invention can significantly reduce the mRNA levels of proinflammatory factors IL-6, IL-1β and TNF-α in the lung tissue of ALI mice induced by LPS, and its anti-inflammatory effect is better than that of monomer Bergapten.

[0144] 5) Effects of Ber-lipo on the fluorescence expression and distribution of macrophage polarization indicators CD86, iNOS, CD163 and CD206 in the lung tissue of LPS-induced ALI model mice

[0145] First, the lung paraffin sections were antigen repaired, and then the immunofluorescence staining of lung tissue sections was performed according to the cell immunofluorescence staining procedure. The primary antibodies used included CD86 (Proteintech, 13395-1-AP, 1:200), CD163 (Proteintech, 16646-1-AP, 1:200), CD206 (Proteintech, 60143-1-Ig, 1:200) and iNOS (Santa Cruz, sc-7271, 1:100), and the secondary antibodies used included donkey anti-rabbit Cy3 (Biolegend, 406402, 1:200) and goat anti-mouse Cy3 (Biolegend, 405309, 1:200). Finally, the sections were sealed and photographed under a 40× oil immersion lens of a confocal microscope.

[0146] Fig.18 The results showed that Ber-lipo of the present invention can significantly inhibit the fluorescence intensity of M1 macrophage polarization CD86 and iNOS, and significantly increase the fluorescence intensity of M2 macrophage polarization indicators CD163 and CD206, that is, inhibit M1 polarization and promote M2 polarization.

[0147] 6) Effect of Ber-lipo on the protein expression of macrophage polarization indicators CD86, CD163 and CD206 in the lung tissue of LPS-induced ALI model mice

[0148] Take 50mg lung tissue in a centrifuge tube, add RIPA, PMSF and phosphatase inhibitors at a ratio of 100:1:1, add magnetic beads to homogenize the tissue, centrifuge at 4℃ and 12000rpm for 10min, collect the supernatant and use BCA kit to measure protein concentration. Add 5×SDS-PAGE protein loading buffer to the lung tissue protein sample with the measured concentration, boil at 95℃ for 10min, load the sample onto the prepared gel, and perform SDS-PAGE electrophoresis separation at 80v for 30min, 120v for 1.5h, and transfer to the membrane at 250mA for 2h after the electrophoresis. After the transfer, the membrane was transferred to a 5% skim milk powder culture dish and blocked for 2 hours on a shaker. Then, the membrane was incubated with primary antibodies of CD86 (Proteintech, 13395-1-AP, 1:2000), CD163 (Proteintech, 16646-1-AP, 1:1000) and CD206 (Proteintech, 60143-1-Ig, 1:10000) protein molecules at 4°C overnight. The next day, the membrane was washed with TBST and incubated with the corresponding secondary antibody at room temperature for 1 hour. Finally, the protein bands on the membrane were imaged using a chemiluminescence imaging system.

[0149] Fig.19 and Fig. 20 The results showed that compared with the model group, CD86 in the Bergapten and Ber-lipo groups was significantly decreased, CD163 and CD206 were significantly increased, and the difference between Bergapten and Ber-lipo was significant and statistically significant, which indicates that Ber-lipo of the present invention can significantly inhibit the polarization of M1 macrophages in lung tissue and promote the polarization of M2 macrophages, and the effect is better than free Bergapten.

[0150] 7) Effect of Ber-lipo on the mRNA expression of macrophage polarization indicators CD86, iNOS, CD163 and CD206 in the lung tissue of LPS-induced ALI model mice

[0151] Total RNA from lung tissue was extracted according to the instructions of RNA extraction kit (Tiangen Biotechnology, DP419), the extracted RNA content was determined by Nanodrop, and the mRNA was reverse transcribed into cDNA using PrimeScript RT kit (Takara, RR047B). The cDNA of each sample was used as a template to perform qRT-PCR amplification and detection of the mRNA expression of each target gene (CD86, iNOS, CD163 and CD206). After the reaction, Tubulin was used as the internal reference gene and 2 -ΔΔCT Methods The relative expression of each gene was calculated. The primer sequences used are as follows:

[0152] CD86-F:CGCAAGCTTATTTCAATGGGA;

[0153] CD86-R:CCTGCCAAAATACTACCAG;

[0154] iNOS-F:GGAATCTTGGAGCGAGTTGT;

[0155] iNOS-R:CCTCTTGTCTTTGACCCAGTAG;

[0156] CD206-F:TTCCGTCACCCTGTATGCC;

[0157] CD206-R:TAACTCTGTGCCCTTGATTCCA;

[0158] Tubulin-F:AGCAGCTACTTTGTGGAGTG;

[0159] Tubulin-R:TCGGAGATGCGCTTGAATAG;

[0160] CD163-F:AATCCCAGACACTATTGCCAT;

[0161] CD163-R:CTCCACCTACCAAGCGAAG.

[0162] Fig.21 The results showed that Ber-lipo of the present invention significantly reduced CD86 and iNOS mRNA, inhibited the polarization of M1 macrophages in lung tissue, significantly increased CD163 and CD206 mRNA, promoted M2 macrophage polarization, and the effect of Ber-lipo was better than that of monomer Bergapten.

[0163] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. An inhalable bergamot lactone nanoliposome, comprising a raw drug and a carrier, characterized in that: The original drug is bergamot lactone, the carrier is DPPC, cholesterol and mPEG2000-DSPE, and the molar ratio of DPPC, cholesterol and mPEG2000-DSPE in the carrier is (70-85): (15-25):

3.

2. The inhalable bergamot lactone nanoliposome according to claim 1, characterized in that: The molar ratio of bergamot lactone to DPPC in the inhalable bergamot lactone nanoliposome is 1:(1.5-4.5).

3. The inhalable bergamot lactone nanoliposome according to claim 1, characterized in that: The drug loading amount of bergamot lactone in the bergamot lactone nanoliposome is 0.45% to 0.60%.

4. The inhalable bergamot lactone nanoliposome according to claim 1, characterized in that: The encapsulation rate of bergamot lactone by the bergamot lactone nanoliposome is 5% to 8%.

5. The inhalable bergamot lactone nanoliposome according to claim 1, characterized in that: The zeta potential of the bergamot lactone nanoliposome is -6 to -8 mV.

6. The method for preparing the inhalable bergamot lactone nanoliposome according to any one of claims 1 to 5, characterized in that: The steps include: S1. dissolving DPPC, cholesterol, mPEG2000-DSPE and bergamot lactone in a solvent, and removing the solvent to form a film; S2. Add an aqueous medium to the film formed in step S1, and fully hydrate and peel off the film at 50-70° C. to obtain inhalable bergamot lactone nanoliposomes.

7. Use of the inhalable bergamot lactone nanoliposomes according to any one of claims 1 to 5 in the preparation of a drug for treating acute lung injury.

8. The use according to claim 7, characterized in that: The administration method of the drug for treating acute lung injury is aerosol inhalation administration.

9. Use of the inhalable bergamot lactone nanoliposome according to any one of claims 1 to 5 in a drug for inhibiting the expression of M1 macrophages.

10. Use of the inhalable bergamot lactone nanoliposomes according to any one of claims 1 to 5 in a drug for promoting the expression of M2 macrophages.

Citation Information

Patent Citations

  • Targeted magnetic nanometer nano-liposome and preparation method thereof

    CN107441505A

  • Bergamolactone liposome and preparation method thereof, encapsulation rate determination method, bergamolactone liposome gel and preparation method thereof

    CN116617164A

Cited By

  • Inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and preparation method of inhalation type pharmaceutical composition

    CN121445816A